Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 1

Completed

Conditions: Primary Peritoneal Cancer
Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: Paclitaxel,
Drug: Bevacizumab
Drug: Cisplatin
Drug: Olaparib

First Posted Date: 2014-04-24

Last Posted Date: 2020-08-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT02121990

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History

Active, not recruiting

Conditions: Breast Cancer Survivors

First Posted Date: 2014-04-24

Last Posted Date: 2024-12-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 499

Registration Number: NCT02122107

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
City of Hope, Duarte, California, United States

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Phase 1

Completed

Conditions: Stage IV Lung Adenocarcinoma

Interventions: Drug: Certolizumab
Drug: cisplatin
Drug: pemetrexed

First Posted Date: 2014-04-23

Last Posted Date: 2023-01-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT02120807

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States

and more 3 locations

Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer

Not Applicable

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Device: Calypso Beacon Implantation

First Posted Date: 2014-04-11

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 48

Registration Number: NCT02111681

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

and more 1 locations

Meaning-Centered Counseling for Chinese Patients Who Are Being Treated for Advanced Cancer

Recruiting

Conditions: Advanced Cancer

Interventions: Behavioral: In-depth Patient Interviews
Behavioral: Adaptation of IMCP for Chinese Immigrant Cancer Patients
Behavioral: Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)

First Posted Date: 2014-04-11

Last Posted Date: 2025-03-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 93

Registration Number: NCT02112188

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 6 locations

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: apalutamide
Drug: Everolimus

First Posted Date: 2014-04-08

Last Posted Date: 2023-05-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT02106507

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases

Phase 1

Active, not recruiting

Conditions: Head and Neck Melanoma

Interventions: Drug: fluorescent cRGDY-PEG-Cy5.5-C dots

First Posted Date: 2014-04-08

Last Posted Date: 2025-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 67

Registration Number: NCT02106598

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Weill Cornell Medical Center, New York, New York, United States

Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors

Active, not recruiting

Conditions: Hodgkin Lymphoma Survivor

Interventions: Other: Clinical Assessment
Procedure: Stress cardiac MRI
Procedure: Stress echocardiogram

First Posted Date: 2014-04-08

Last Posted Date: 2025-05-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 133

Registration Number: NCT02106611

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Not Applicable

Completed

Conditions: Neuroblastoma

Interventions: Biological: Anti-GD2 3F8 Monoclonal Antibody
Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor)
Drug: oral isotretinoin

First Posted Date: 2014-04-01

Last Posted Date: 2020-02-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 69

Registration Number: NCT02100930

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Germ Cell Tumor and Testicular Tumor DNA Registry

Recruiting

Conditions: Germ Cell Tumor
Testicular Tumor

Interventions: Behavioral: Questionnaires
Other: sample of blood or saliva

First Posted Date: 2014-03-31

Last Posted Date: 2024-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1000

Registration Number: NCT02099734

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy